Investigational

Related by string. investigational * * investigational compounds . Investigational Device Exemption IDE . investigational compound . Investigational Device Exemption . Investigational NDAs . investigational drug . investigational oral . investigational mTOR inhibitor . IND Investigational New . includes investigational compounds . Investigational Drug . investigational therapies *

Related by context. All words. (Click for frequent words.) 72 IND Investigational New 68 New Drug IND 67 investigational 67 INDs 66 IND 66 New Drug Application 63 Drug Submission 63 Investigational Device Exemption 63 Investigational Device Exemption IDE 62 IND submission 61 Marketing Authorization Application 61 Biologics License Application 60 Biologic License Application 60 Biologics License Application BLA 60 Drug Applications NDAs 59 IND enabling 59 Pivotal Phase III 59 Clinical Trial 59 Phase III clinical trials 59 Premarket Approval PMA 58 clinical trials 58 preclinical toxicology 58 Phase 2a Trial 58 Biologic License Application BLA 58 FDA Approvable Letter 58 Clinical Trial Application 58 Luveniq 58 Phase III Clinical Trial 58 Marketing Authorisation Application 58 Market Approval PMA 58 Drug Applications INDs 58 Files Investigational 58 Phase III Clinical Trials 58 Phase III clinical 58 Phase IIb 58 Marketing Authorization Application MAA 57 Phase IIa 57 BLA submission 57 RNAi Therapeutic 57 preclinical 57 Phase IIb Clinical Trial 57 BLA filing 57 FDA Accepts 57 Chemical Entity NCE 57 IND Application 56 Phase III trials 56 Phase IIa trial 56 Phase Ib 56 Phase IIb Trial 56 Zingo TM 56 GLP toxicology studies 56 Civacir 56 clinical trial 56 Orphan Drug Designation 56 Preclinical Data 56 Panzem R 56 NDA submission 56 investigational humanized monoclonal antibody 56 Files IND 56 Vilazodone 56 Orphan Drug Status 56 Premarket Approval 56 phase IIa 56 Patient Enrollment 56 FOLOTYN ® 56 Pivotal Study 56 Phase 2b study 55 Phase III 55 Phase Ib study 55 pivotal Phase III 55 Completes Patient Enrollment 55 Drug Submission NDS 55 Fast Track Designation 55 Cethromycin 55 Pivotal Trial 55 Clinical Trial Results 55 Initiates Clinical 55 sBLA 55 Archexin 55 severe hypercholesterolemia 55 Ampligen r 55 Premarket Approval Application 55 initiate Phase 55 PMA submission 55 II Clinical Trial 55 ATL# [001] 55 Fast Track Status 55 Iluvien ® 55 lucinactant 55 CDP# 55 CIP TRAMADOL ER 55 Phase 2b Clinical Trial 55 Accelerated Approval 55 Fast Track designation 55 Phase III Pivotal 55 Corlux 55 Soliris eculizumab 55 Voraxaze 55 Fx #A 55 Complete Response 55 Phase 2a 55 NDA Submission 55 Roflumilast 55 Pivotal Phase 54 Phase 2a trial 54 Successfully Completes Phase 54 Aurora Kinase 54 Initiate Phase 54 Receives Orphan Drug Designation 54 Approvable Letter 54 ANDAs 54 Drug Candidate 54 Dalbavancin 54 Initiate Clinical Trial 54 LEVADEX TM 54 KRN# 54 Novel Antibiotic 54 sNDA 54 Phase IIa Clinical Trial 54 prGCD 54 ADVEXIN p# therapy 54 Marketing Authorisation Application MAA 54 Phase 2a clinical 54 GATTEX TM 54 lomitapide 54 Application BLA 54 Clinical Study 54 Oxytrex TM 54 Collaborators Publish 54 Prodrug 54 rolling Biologics License 54 PLK1 SNALP 54 Ceftobiprole 54 SinuNase TM 54 Cellegesic 54 Phase IIa clinical trials 54 phase IIb clinical 54 Phase IIB 54 Drug Application 54 Orathecin 54 Biological License Application 54 Augment Injectable 54 Arimoclomol 54 Orphan Status 54 LymphoStat B TM 54 Phase IIa clinical 54 Personalized Immunotherapy 54 Orphan Drug 54 vilazodone 54 Biomarker Study 54 phase IIa clinical 54 Romidepsin 54 RNAi Therapeutics 54 CEQ# 54 VitiGam 54 Lixisenatide 54 Dupuytren Contracture 54 Milnacipran 54 Welichem 54 orphan designation 53 Initiates Phase II 53 Traficet EN 53 GENTAMICIN SURGICAL IMPLANT 53 Phase 2b trial 53 Biologics Licensing 53 DAVANAT ® 53 Teflaro 53 Bazedoxifene 53 registrational 53 FDA Investigational Device 53 Pivotal Clinical Trial 53 preclinical studies 53 UPLYSO 53 Phase IIb trials 53 Pivotal Trials 53 Investigational Compound 53 Maribavir 53 Chemical Entity 53 Marketing Approval PMA 53 Hsp# Inhibitor 53 Sanvar R 53 AP# [003] 53 Chemokine Therapeutics 53 Phase III Trial 53 Zelrix 53 PrevOnco 53 Vitaros 53 application sNDA 53 Zenvia Phase III 53 PDE4 inhibitor 53 Begin Clinical Trials 53 LibiGel ® 53 XOMA 3AB 53 Linjeta TM 53 trastuzumab DM1 T DM1 53 Investigational Treatment 53 Antiangiogenic 53 Phase 2a clinical trials 53 Aerosurf 53 Onconase 53 Elagolix 53 Monoclonal Antibody 53 Factor VIIa 53 QRxPharma 53 nonclinical studies 53 Safinamide 53 Ridaforolimus 53 Phase IIIb clinical 53 Meets Primary Endpoint 53 ICA # 53 IND CTA 53 Glybera R 53 EGRIFTA TM 53 Initiates Enrollment 53 FDA Clearance 53 PREOS R 53 LUCASSIN 53 Phase IIa trials 53 Phase III Trials 53 ARRY # 53 Patent Broadly Covering 53 k premarket 53 Icatibant 53 Ofatumumab 53 oral prodrug 53 investigational drug 53 Submits Investigational 53 Iluvien TM 53 OMNARIS HFA 53 Pirfenidone 53 tiapamil 53 HepaGam B 53 Golimumab 53 LUVENIQ 53 PNP inhibitor 53 Sapacitabine 53 NEUMUNE 53 PSN# [002] 53 ALN PCS 53 rxRNA 53 Phase II 53 RhuDex ® 53 Soliris TM eculizumab 53 Alvesco R 53 Phase IIb clinical trials 53 Small Molecule 53 lorcaserin NDA 53 Present Preclinical Data 53 zileuton CR 53 Patent Covering 53 submit Biologics License 53 Inc. OTCBB SYBD 53 Recombinant Human 53 Cimzia TM 53 Phase 2b Trial 52 targeted radiotherapeutic 52 investigational pan BCR 52 Junovan 52 INCB# [001] 52 MOZOBIL 52 Phase IIb trial 52 ZEVALIN ® 52 Reports Preclinical Data 52 IL# PE#QQR 52 acyclovir Lauriad R 52 Omacetaxine 52 Curaxin 52 Dapagliflozin 52 granted Ortec 52 Davanat 52 Phenoptin 52 SYCREST 52 Contrave NDA 52 phase IIb trial 52 Oral Insulin 52 Presents Positive Preclinical 52 CCR5 antagonist 52 Bremelanotide 52 ALN TTR 52 Presents Positive 52 Virulizin R 52 ongoing Phase 1b 52 PDUFA Date 52 Kamada AAT 52 Phase Ib clinical 52 liver resection surgeries 52 Orphan Drug designation 52 alogliptin 52 oral methylnaltrexone 52 Universal Flu Vaccine 52 Inhaled Liposomal Ciprofloxacin 52 include Phenoptin TM 52 cGMP manufacture 52 IMC #B 52 Pafuramidine 52 Phase #b/#a 52 Submits NDA 52 Vion Pharmaceuticals 52 Ustekinumab 52 Presents Preclinical Data 52 RNAi therapeutic 52 supplemental Biologics License Application 52 PDX pralatrexate 52 HDAC Inhibitor 52 Flutiform ™ 52 dalbavancin 52 Valortim TM 52 Indaflex TM 52 Protalix BioTherapeutics 52 Therapeutic Competitors Companies 52 Humanitarian Device Exemption 52 PEG SN# 52 FDA Approval 52 Phase IIb clinical 52 Submits Supplemental 52 PRX # 52 JAK inhibitor 52 alvimopan 52 Restanza 52 Oral Calcitonin 52 Marqibo 52 TRX1 52 tafamidis 52 Phase 1b clinical 52 StaphVAX R 52 Phase 2b 52 EVIZON TM 52 Lenocta TM 52 IND Filing 52 Trofex 52 Phase III psoriasis 52 Ampligen 52 tezampanel 52 Dyloject TM 52 Gendux 52 Pharmacokinetic Study 52 molecular imaging radiopharmaceutical 52 Onco TCS 52 OLpur TM H2H 52 Cintredekin Besudotox 52 #D#C# 52 Oracea TM 52 OncoVEX GM CSF 52 Cloretazine ® 52 CLIA waiver 52 Pegloticase 52 Provisional Patent 52 pivotal bioequivalence 52 Dacogen injection 52 ABL inhibitor 52 Caprospinol 52 GeneICE 52 EndoTAG TM -1 52 JAK2 Inhibitor 52 Fast Track designations 52 MEK inhibitor 52 AAG geldanamycin analog 52 faropenem medoxomil 52 Urocidin 52 Immunotherapeutic 52 OMAPRO ™ 52 Ampligen ® 52 Onrigin 52 non nucleoside inhibitor 52 NexACT 52 PROGENSA R 52 Expedited Review 52 Fixed Dose Combination 52 Arzerra ofatumumab 52 PNT# 52 Daclizumab 51 PHX# 51 Saxagliptin 51 histone deacetylase HDAC inhibitor 51 CRMD# 51 Exherin TM 51 Plenaxis TM 51 Loramyc R 51 rALLy trial 51 Friedreich Ataxia FRDA 51 SUTENT ® 51 miRNA therapeutics 51 DOS# 51 ruxolitinib 51 Shigamabs R 51 investigational compound 51 antibody MAb 51 Completes Enrollment 51 Clevudine 51 ALN TTR# 51 Clofarabine 51 Satraplatin 51 peginesatide 51 InNexus Biotechnology 51 Anthim 51 Prolongs Survival 51 Dose Ranging Study 51 ThermoDox R 51 indiplon capsules 51 methylnaltrexone 51 Panzem 51 NDA resubmission 51 Addrenex 51 tolevamer 51 Ampligen R 51 Japanese Encephalitis vaccine 51 Nasdaq HALO 51 NEBIDO R 51 product platforms AZX# 51 Aryplase 51 Tamibarotene 51 Simulect 51 Augment TM 51 COPREXA 51 Treatment Resistant 51 Phase #b/#a clinical 51 phase Ib 51 OvaRex R 51 PS# [001] 51 Iloperidone 51 CG# [003] 51 MAA submission 51 TBC# 51 PD LID 51 Granted Orphan Drug 51 preclinical efficacy 51 ganetespib 51 topically applied SEPA 51 Frova ® 51 MBP# [001] 51 Rhucin 51 Restanza TM 51 Fodosine 51 Guanilib 51 Therapeutic Vaccine 51 Tissue Repair 51 product candidate Lpathomab 51 Anidulafungin 51 Boceprevir 51 PIX# trial 51 candidate REP# 51 refractory Hodgkin lymphoma 51 ONCONASE 51 injectable formulation 51 Extended Release 51 IMA# 51 hoFH 51 humanized anti 51 Microplasmin 51 Receptor Agonist 51 Exocrine Pancreatic Insufficiency 51 Augment Bone Graft 51 Investigational Drug 51 Glatiramer Acetate 51 HIV integrase inhibitor 51 Perifosine 51 Phase 2a Clinical Trial 51 Zenvia ™ 51 Anti CD# Antibody 51 MOR# 51 REMOXY R 51 inhaled formulation 51 RhuDex 51 Mipomersen 51 Orphan Drug designations 51 JAK Inhibitor 51 Naproxcinod 51 Enzyme Replacement Therapy 51 supplemental biologics 51 Preclinical studies suggest 51 registrational studies 51 POSIDUR TM ELADUR TM 51 APF# NDA 51 Trodusquemine MSI 51 HCV protease inhibitor 51 midstage trials 51 Cannabinor 51 Xcytrin R 51 Collategene 51 orally administered 51 MAXY VII 51 Phase 1b 51 Apricus Bio 51 CD# CEA 51 Plicera 51 Pruvel 51 teduglutide 51 TRANSDUR Sufentanil 51 Nimotuzumab 51 Aliskiren 51 Supplemental Biologics License Application 51 ELND# 51 GENERIC SILDENAFIL SOFT Generic 51 Velaglucerase Alfa 51 QLT# 51 Advanced Melanoma 51 submitted Biologics License 51 Chemokine Receptor 51 TKB# 51 OvaRex ® MAb 51 Pfizer maraviroc 51 Rescula 51 AeroLEF TM 51 FDA approvable letter 51 LEUKINE 51 Actemra tocilizumab 51 ocular formulation 51 ATPace TM 51 Sym# 51 Phase 1b trial 51 Bronchitol 51 MK #B 51 ALN HTT 51 PANVAC VF 51 diarrhea predominant irritable 51 Augment ™ 51 huC# DM4 51 MONOVISC 51 Integrase Inhibitor 51 Liprotamase 51 rhC1INH 51 IAP inhibitors 51 Telatinib 51 VEGF Trap 51 Phase III pivotal 51 Aganocide 51 PREOS 51 generation URAT1 inhibitor 51 Oxycyte ® 51 miconazole Lauriad R 51 RECOTHROM R 51 ALGRX 51 Junovan TM 51 Octreotide 51 IAP inhibitor 51 triphendiol 51 Phase IIb III 51 MAGE A3 ASCI 51 Intermezzo R 51 casopitant 51 Sanctura XR 51 RDEA# 51 Milestone Payment 51 OTC BB PVCT 51 Cimzia ® 51 Rhucin ® 51 Submits IND 51 phase Ib clinical 51 therapeutic monoclonal antibodies 51 FDA Complete Response 51 alvimopan Investigational 51 Deferiprone 51 ATL# [002] 51 Cardiac Cryoablation System 51 Allovectin 7 R 51 MEK Inhibitor 51 GALNS 51 AZILECT R 51 Ceflatonin 51 ONGLYZA ™ 51 EOquin 50 Fibrillex TM 50 Fibrin Sealant 50 generation purine nucleoside 50 SILENOR 50 ADVANCE PD 50 Annamycin 50 Phase Ib II 50 Loxapine 50 torezolid phosphate 50 subcutaneous formulation 50 AlphaRx 50 vemurafenib 50 carcinogenicity study 50 FDA Orphan Drug 50 Tarceva TM 50 EnzymeRx 50 ILUVIEN ® 50 Tolvaptan 50 Clinical Trials 50 Omapro 50 Submits Biologics License Application 50 TREANDA 50 Efficacy Results 50 Vascugel 50 liprotamase 50 mertansine 50 Initiates Clinical Trial 50 Serdaxin 50 Schizophrenia Drug 50 ProLindac TM 50 SparVax TM 50 topically administered 50 Investigational Oral 50 Clinical Trial Evaluating 50 AQ4N 50 ASONEP 50 Ozarelix 50 TachoSil 50 ADX# 50 MGCD# [001] 50 LEVADEX ™ 50 Tesetaxel 50 AMPAKINE CX# 50 cannabinor 50 Excellagen 50 Ferumoxytol 50 Eculizumab 50 OncoVEX 50 Cladribine Tablets 50 Javelin Pharmaceuticals AMEX JAV 50 NVA# 50 Surfaxin LS 50 Telavancin 50 Fingolimod 50 PrevOnco ™ 50 REPEL CV 50 Ceflatonin R 50 proprietary transdermal patch 50 Vaccine Candidate 50 Homspera 50 Anavex #-# 50 BLP# Liposome Vaccine 50 RNAi therapeutic targeting 50 JAK1 50 sumatriptan DosePro 50 candidate deforolimus 50 Dermylex TM 50 Triolex 50 NICOSAN TM 50 NEBIDO 50 Ramoplanin 50 including eniluracil ADH 50 Zensana 50 CIMZIA r 50 Circ Pharma 50 Excellarate 50 Vicriviroc 50 midstage clinical trials 50 TYZEKA 50 PF # [002] 50 R#/MEM # 50 Therapeutic Antibodies 50 Aflibercept 50 Molecular Diagnostic Test 50 DermTech International 50 Perflubutane Polymer Microspheres 50 Drug Shows Promise 50 ZFP Therapeutic 50 Cerepro ® 50 Marketing Authorization 50 ADVEXIN 50 Li Fraumeni Syndrome 50 Lupus Drug 50 Prostate Cancer Vaccine 50 Submits Response 50 Fabry Disease 50 SAR# [004] 50 GTC recombinant human 50 TMC# [002] 50 CINTREDEKIN BESUDOTOX 50 RAPAFLO 50 Genasense ® 50 Ramelteon 50 OHR/AVR# 50 autologous cellular immunotherapy 50 OvaDx 50 pexiganan 50 SNT MC# 50 Romiplostim 50 HoFH 50 MKC# MKC# PP 50 Levoleucovorin 50 Psoriasis Drug 50 Pennsaid R 50 Pralatrexate 50 Systemic Sclerosis 50 taliglucerase alfa 50 Crofelemer 50 BRIM2 50 balsalazide tablet 50 Hedgehog Pathway Inhibitor 50 Carfilzomib 50 Study Evaluating 50 compound ISA# 50 Onalta ™ 50 Alemtuzumab 50 ZEGERID Chewable Tablets 50 Gout Drug 50 Cardioxyl Pharmaceuticals 50 Blinatumomab 50 Hematological Malignancies 50 Ercole Biotech 50 Emezine 50 Hematological Cancers 50 proteasome inhibitor 50 Amrubicin 50 Phase 2b clinical 50 Qutenza TM 50 Urokinase 50 OMAPRO 50 ORENCIA R 50 ONCONASE R 50 MelaFind ® 50 CB2 selective receptor agonist 50 phase IIb 50 IDX# 50 Interferon Alpha 50 vidofludimus 50 AzaSite Plus 50 Velcade bortezomib 50 Exalgo TM 50 BAL# [002] 50 Phase 1a clinical 50 Commence Phase 50 Nasdaq VRTX 50 intravenous acetaminophen 50 ketolide antibiotic 50 maribavir 50 Resubmission 50 Begins Dosing 50 TAFA# 50 LentiVector technology 50 MyVax R 50 Onalta 50 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 50 Protexia R 50 pharmacological chaperone 50 Mutual Recognition Procedure 50 Metformin GR 50 BEMA Fentanyl 50 mitogen activated ERK kinase 50 Aloxi Injection 50 Natalizumab 50 orphan drug 50 Generx ™ 50 Antisense Drug 50 M Enoxaparin 50 Ceragenix 50 talactoferrin 50 CryoSeal 50 pharmacokinetic PK 50 Keryx Biopharma 50 IRX 2 50 aripiprazole Abilify 50 XYOTAX TM 50 ENTEREG ® 50 Mozobil 50 DC Bead 50 PROPEL trial 50 Telaprevir 50 pralatrexate injection folate analogue 50 FDA Approvals 50 Prodarsan ® 50 L BLP# 50 GLPG# 50 BioDelivery Sciences 50 Receives Orphan Drug 50 Extended Release Capsules 50 BEMA TM Fentanyl 50 pivotal Phase 50 Long Term Efficacy 50 NASDAQ INGN 50 Phase #/#a 50 Elesclomol 50 VitiGam TM 50 SURFAXIN 50 relapsed leukemia 50 sNDA submission 50 tasimelteon 50 HepeX B 50 ATryn R 50 IMVAMUNE R 50 Receives Approvable Letter 50 Combination REOLYSIN R 50 adalimumab Humira 50 Therapeutic Efficacy 50 Pulmonary Arterial Hypertension 50 Ecallantide 50 Receives Milestone Payment 50 Rhucin R 50 KineMed 50 Albugon 50 Loramyc ® 50 Phase 2b clinical trials 50 Anturol TM 50 Anticancer Agent 50 herpetic keratitis 50 Thrombin 50 confirmatory Phase 3 50 ACV1 50 CBLB# 50 Tezampanel 50 anticancer agent 50 Acute Radiation Syndrome ARS 50 dose escalation clinical 50 Ixabepilone 50 zolpidem tartrate sublingual tablet 50 Earns Milestone Payment 50 Phase lll 50 Anti Tumor Activity 50 motexafin gadolinium Injection 50 Systemic Delivery 50 APF# 50 Aegerion 50 Anti Tumor 50 Lung Cancer Drug 50 Belinostat 50 vismodegib 50 Santhera 50 Marketing Authorization Applications 50 AeroLEF 50 Fidaxomicin 50 Valortim 50 mTOR inhibitor 50 Firazyr 50 Cinryze ™ 50 drug pipeline TAFA# 50 ANTEGREN 50 Cutaneous T 50 Maxy G# 50 Vaccinogen 50 Celsion Corporation 50 Pandemic Influenza Vaccine 50 Oral Spray 50 Transcept Pharmaceuticals 50 Cerashield 50 HCV polymerase inhibitor 50 Use Authorization EUA 50 vivo preclinical 49 mGluR5 negative 49 Therapy Evaluation 49 Orazol 49 LUMINATE 49 TPI ASM8 49 investigational antibiotic 49 Ocular Drug 49 PreHistin TM 49 Panzem R NCD 49 OMP #R# 49 seliciclib CYC# 49 Liposomal 49 defensin mimetic antibiotic 49 Expression Genetics 49 KRYSTEXXA TM 49 JAK2 inhibitor 49 Tumor Targeting 49 Bioral ® 49 Aurora kinase inhibitor 49 Advexin 49 Glaucoma Treatment 49 ZEFTERA ™ 49 Taro Receives 49 Indaflex 49 Urocidin TM 49 Pazopanib 49 Stedesa 49 Serdolect ® 49 k Premarket Notification 49 KRYSTEXXA TM pegloticase 49 Cardio Vascu Grow 49 Humira adalimumab 49 severe gastroparesis 49 Arcalyst 49 Aviptadil 49 PROSTASCINT R 49 Phase IIIb study 49 Orphan Drug status 49 Completes Patient Enrolment 49 selective androgen receptor modulator 49 targeting CD# 49 carcinogenicity studies 49 RiVax 49 Protexia ® 49 Prodarsan 49 compound PMX # 49 bosutinib 49 DASISION 49 Peramivir 49 multicenter Phase III 49 forodesine 49 Efficacy Trial 49 omacetaxine mepesuccinate 49 oral antiviral 49 BEMA Buprenorphine 49 albiglutide 49 ALKS 49 RenaZorb TM 49 TRANSDUR Bupivacaine 49 vascular disrupting agent 49 personalized immunotherapy 49 drug GAP #B# 49 orally dosed 49 TolerRx 49 BLOOM DM 49 omacetaxine 49 Approvable 49 ZEFTERA TM Zevtera TM 49 ImQuest Pharmaceuticals 49 Prodarsan R 49 Cethrin 49 relapsed multiple myeloma 49 Patents Covering 49 Combidex 49 Elvitegravir 49 apaziquone 49 Awarded Qualifying Therapeutic 49 Cancer Vaccines 49 HEPLISAV TM 49 Initiated Phase 49 Kinase Inhibitor 49 brentuximab vedotin 49 Clinical Study Shows 49 fluvoxamine maleate 49 Regenerative Cells 49 confirmatory Phase III 49 Phase III confirmatory 49 Bone Graft 49 pharmacokinetic studies 49 OTCBB IMUC 49 STEDESA 49 refractory APL 49 NexACT ® 49 investigational antiplatelet agent 49 Cladribine 49 Cleviprex TM clevidipine 49 HCV Protease Inhibitor 49 Novel Oral 49 Phase 1b Clinical Trial 49 paliperidone palmitate 49 Acetavance TM 49 VIVITROL ® 49 therapeutic monoclonal antibody 49 Commercialization Agreement 49 Zybrestat 49 Tranzyme Pharma 49 H#N# VLP vaccine 49 Dr. Arndt Schottelius 49 Wound Dressing 49 NUEDEXTA ™ 49 Ocrelizumab 49 Prednisporin TM 49 lorvotuzumab mertansine 49 Tyrosine Kinase Inhibitor 49 methylnaltrexone bromide 49 registrational trial 49 file INDs 49 Pivotal Phase II 49 GSK# [001] 49 Gamunex C 49 oral ridaforolimus 49 Spiegelmer ® 49 ibuprofen Injection 49 Bioral R 49 KNS # 49 Centralized Procedure 49 lurasidone 49 Panzem ® 49 allosteric modulator PAM 49 Phase #b/#a trial 49 Avanafil 49 Anti Inflammatory Drug 49 pseudobulbar affect PBA 49 ImmunoCellular Therapeutics 49 Antibody Drug Conjugate 49 Adentri 49 rilonacept 49 T Pred 49 QNEXA 49 Antiviral Activity 49 EP #R 49 Tesamorelin 49 isavuconazole 49 SARMs 49 Preclinical Efficacy 49 CIP Fenofibrate 49 Proxinium TM 49 dasatinib Sprycel ® 49 ISO Vorin TM 49 ZEGERID Capsules 49 Hepatitis C Virus HCV 49 exon skipping 49 Administration TGA 49 FlutiformTM 49 generation calcineurin inhibitor 49 PROVENGE sipuleucel T 49 Bavituximab 49 MIS# 49 ALN VSP 49 Bioral Amphotericin B 49 IgG1 monoclonal antibody 49 PDUFA Prescription Drug 49 Uvidem 49 Diabetic Nephropathy 49 Alogliptin 49 Ketotransdel 49 Bicifadine 49 diabetic neuropathic pain 49 PSN# [001]

Back to home page